{"doi":"10.1177/155989771414007","title":"Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer","abstract":null,"journal":"MD Conference Express","year":2014,"id":602098,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1544080,"name":"M. J. Piccart-Gebhart","orcid":null,"position":1,"is_corresponding":false},{"id":1544079,"name":"B. Hoyle","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer","abstract":"This article presents results of the global, Phase 3, randomized Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study; BIG 2–06/N063D [ALTTO; NCT00490139], conducted with more than 8300 women with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. This study evaluated concurrent or sequential adjuvant lapatinib plus trastuzumab. Although the combination is safe, the primary endpoint of improved disease-free survival was not met.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W2326908302","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://doi.org/10.1177/155989771414007","host_type":"conference"}],"fields_of_study":["HER2/EGFR in Cancer Research","Peptidase Inhibition and Analysis","Monoclonal and Polyclonal Antibodies Research"],"mesh_terms":[],"keywords":["Trastuzumab","Lapatinib","Medicine","Adjuvant","Oncology","Breast cancer","Internal medicine","Human Epidermal Growth Factor Receptor 2","Clinical endpoint","Cancer","Clinical trial"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Gender equality"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T18:18:11.515595Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}